New schizophrenia drug could ‘change the lives of millions of people’
The US Food and Drug Administration has approved the new drug Cobenfy, which is owned by pharmaceutical firm Bristol Myers ...
technologynetworks4m
FDA Approves First Schizophrenia Treatment With a Novel Target in 70 Years
The US Food and Drug Administration has granted approval to Bristol-Myers Squibb’s drug Cobenfy® (xanomeline and trospium ...
Bristol Myers Stock Jumps. Why FDA Approval for Its Schizophrenia Drug Is Groundbreaking.
Bristol Myers Squibb stock jumped after the pharma company won approval for its new schizophrenia drug late Thursday. “This ...
kffhealthnews35m
Antipsychotic Drug Cobenfy Wins FDA Approval For Schizophrenia Treatment
The Bristol Myers Squibb medicine is said relieve symptoms without causing some of the harsh side effects of drugs already in use. Meanwhile, thousands of patients allege in a lawsuit that drugs used ...
Investor's Business Daily on MSN47m
Bristol-Myers Squibb's Novel Schizophrenia Drug Wins FDA Approval; BMY Stock Signals Breakout
Bristol-Myers Squibb won Food and Drug Administration approval late Thursday for its novel schizophrenia drug, Cobenfy. BMY ...
Dow Jones Today: Stock Futures Little Changed Ahead of Key Inflation Data
Stock futures were modestly higher ahead of the release of the Federal Reserve's preferred measures of inflation, as major ...
Managed Healthcare Executive50m
FDA Approves the Oral Medication KarXT for Schizophrenia
KarXT — now with the brand name Cobenfy— is expected to be available in October with a list price of about $22,500 annually. The drug represents a new way to treat adults with schizophrenia.